Developer docs
API playgroundTry for free, no card

Search company profiles

Vela Diagnostics Pte. Ltd.

Full company profile

uuid0004jks

Namestring
Vela Diagnostics Pte. Ltd.
Legal namestring
Vela Diagnostics Pte. Ltd.
Websiteurl
veladx.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Vela Diagnostics Pte. Ltd. is a Singapore-headquartered molecular diagnostics company that designs, manufactures, and sells integrated sample-to-result PCR and next-generation sequencing (NGS) solutions under the Sentosa platform brand. The platform combines nucleic acid extraction and PCR setup (Sentosa SX101), template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis and reporting (Sentosa SQ Reporter and Sentosa SA201 Reporter) into a single workflow, with both IVD/CE-IVD cleared and RUO configurations. Vela's assay menu is organized under four sub-brands: ViroKey for virology (SARS-CoV-2 with FDA EUA, monkeypox, HIV, HCV, HBV, CMV genotyping), PathoKey for microbiology and pathogen detection (UTI ID and AMR panels, comprehensive pathogen identification of over 2,000 targets), OncoKey for oncology NGS panels (NSCLC, leukemia, hereditary cancer, pan-cancer), and ViroKey/PathoKey quantitative transplant monitoring tests (BKV, CMV, EBV, HSV, VZV, HHV6).

The company serves four primary customer segments: clinical and hospital laboratories, oncology testing laboratories, research institutions purchasing RUO products, and pharmaceutical partners for companion diagnostics development. Revenue is generated through a mix of one-time instrument sales (Sentosa SX101, SQ301, ST401, SA201, Rotor-Gene Q MDx, GB Analyzer), recurring consumables and reagents (extraction kits, library prep kits, sequencing kits, template kits, chip kits), software licenses (Sentosa SQ Reporter, SA201 Reporter), and pharmaceutical partnering arrangements. The Sentosa platform is CE-IVD certified, with select tests holding FDA EUA, Australian TGA, and CLIA high-complexity authorizations, and the products comply with CFR 21 Part 11 for electronic records and signatures. Go-to-market combines regional direct sales (offices in Singapore for APAC/MEA, Hamburg for EMEA, and Fairfield NJ for the Americas) with a global distributor network, including a new exclusive EMEA distribution agreement with ABL Diagnostics (Euronext: ABLD) effective January 2026.

Vela was founded in 2011, operates with 101-250 employees, and is a subsidiary of Vela Diagnostics Holding Pte Ltd, which owns the registered trademarks for Sentosa, OncoKey, PathoKey, and ViroKey across the US, EU, PRC, and UK. The leadership team is led by Sam Dajani (Chairman and CEO), with Dr. Charlie Lee heading research and development and Scott Cassidy overseeing business development. The company acquired Lifecode's Data Interpretation Assets in May 2016 and received a modest Biomedical Advanced Research and Development Authority (BARDA) award of $225,000 in April 2020. There is no public listing and no disclosed venture or growth equity funding in the source material.

Short descriptiontext

Vela Diagnostics is a Singapore-based molecular diagnostics company providing integrated PCR and NGS sample-to-result solutions on the Sentosa platform. It serves hospital and oncology laboratories, research institutions, and pharmaceutical partners across the Americas, EMEA, and Asia Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics platforms, automated PCR workflows, next-generation sequencing, infectious disease testing, clinical laboratory automation
Industry4 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics Instruments and Assays
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeOne Time License
Description

Sale of automated molecular diagnostics instruments including Sentosa SX101, SQ301, ST401, SA201, RGQ, and GB Analyzer. Instruments sold with perpetual licenses.

veladx.com
2Consumables and Reagents
TypeOne Time License
Description

Recurring sales of PCR and NGS assay kits, extraction kits, library preparation kits, sequencing kits, template kits, and chip kits. Consumables sold in packs of 4-96 tests.

veladx.com
3Software Licenses
TypeOne Time License
Description

Sale of software solutions including Sentosa SQ Reporter and SA Reporter with server and perpetual license options. Includes both IVD and RUO versions.

veladx.com
4Pharma Partnering
TypeLicensing Royalties
Description

Collaborative partnerships with pharmaceutical companies for companion diagnostics development and validation.

veladx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Instrument systems sold with perpetual licenses
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Instruments such as Sentosa SQ301 Sequencer, SX101, ST401, and SA201 are sold as one-time purchases with perpetual licenses. Software (Sentosa SQ Reporter) available as Server and Perpetual License (Item 400133).

veladx.com
2PCR and NGS assay kits sold in pack sizes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Assay kits sold in various pack sizes (e.g., 4x8, 4x16, 4x24, 8 runs, 96 tests) with unit pricing varying by kit type and regulatory status (RUO vs IVD). Extraction kits, sequencing kits, template kits available.

veladx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Sentosa
Description

Automated platform for NGS and PCR testing workflows including instruments SX101, SQ301, ST401, and SA201

veladx.com
+3 more records
Core offering1 text field

Vela Diagnostics designs, manufactures, and sells an integrated sample-to-result molecular diagnostics platform (Sentosa) that combines automated nucleic acid extraction, PCR setup, NGS template preparation, sequencing, and data analysis/reporting instruments, software, and validated assay kits for infectious disease, oncology, and antimicrobial resistance testing in clinical and reference laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 48 samples processed within 2 hours using SX101 automated extraction
+4 more records
Product overview1 text field

Vela Diagnostics is a global provider of integrated molecular diagnostics solutions offering standardized, automated PCR and NGS workflow products. The Sentosa platform provides an integrated sample-to-result system combining nucleic acid extraction (Sentosa SX101), PCR setup, template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis/reporting (Sentosa SQ Reporter, Sentosa SA Reporter). The company offers broad PCR assay portfolios under the ViroKey and PathoKey brands covering infectious diseases (respiratory viruses including SARS-CoV-2, Monkeypox, influenza; virology including HIV, HCV, HBV, CMV; antimicrobial resistance), transplant monitoring (BKV, CMV, EBV, HSV, VZV, HHV6), and oncology (NGS-based cancer panels including OncoKey panels for NSCLC, leukemia, and hereditary cancer). The product ecosystem supports both fully automated high-throughput workflows (with <30 minutes hands-on time) and flexible manual options. The Sentosa platform is CE-IVD certified and FDA-cleared, with regulatory approvals across multiple global markets.

Product and service1 record
1Sentosa SX101
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-28
Description

Strategic channel partnership where ABL Diagnostics becomes the exclusive distributor of Vela's CE-IVD automated PCR and NGS platforms across Europe, Middle East, and Africa (EMEA), starting January 2026 following a non-exclusive transition phase in July 2025. The partnership combines Vela's automation and validated assay portfolio with ABL's specialized PCR/NGS kits, DeepChek NGS software, UltraGene real-time PCR kits, and Nadis electronic medical record system deployed in over 200 hospitals in France. ABL brings over two decades of molecular diagnostics experience and distribution in over 40 countries.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vela Diagnostics Pte. Ltd.

Molecular Diagnostics Instruments and Assaysveladx.com

Vela Diagnostics is a Singapore-based molecular diagnostics company providing integrated PCR and NGS sample-to-result solutions on the Sentosa platform. It serves hospital and oncology laboratories, research institutions, and pharmaceutical partners across the Americas, EMEA, and Asia Pacific.

What Vela Diagnostics Pte. Ltd. does

Vela Diagnostics Pte. Ltd. is a Singapore-headquartered molecular diagnostics company that designs, manufactures, and sells integrated sample-to-result PCR and next-generation sequencing (NGS) solutions under the Sentosa platform brand. The platform combines nucleic acid extraction and PCR setup (Sentosa SX101), template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis and reporting (Sentosa SQ Reporter and Sentosa SA201 Reporter) into a single workflow, with both IVD/CE-IVD cleared and RUO configurations. Vela's assay menu is organized under four sub-brands: ViroKey for virology (SARS-CoV-2 with FDA EUA, monkeypox, HIV, HCV, HBV, CMV genotyping), PathoKey for microbiology and pathogen detection (UTI ID and AMR panels, comprehensive pathogen identification of over 2,000 targets), OncoKey for oncology NGS panels (NSCLC, leukemia, hereditary cancer, pan-cancer), and ViroKey/PathoKey quantitative transplant monitoring tests (BKV, CMV, EBV, HSV, VZV, HHV6).

The company serves four primary customer segments: clinical and hospital laboratories, oncology testing laboratories, research institutions purchasing RUO products, and pharmaceutical partners for companion diagnostics development. Revenue is generated through a mix of one-time instrument sales (Sentosa SX101, SQ301, ST401, SA201, Rotor-Gene Q MDx, GB Analyzer), recurring consumables and reagents (extraction kits, library prep kits, sequencing kits, template kits, chip kits), software licenses (Sentosa SQ Reporter, SA201 Reporter), and pharmaceutical partnering arrangements. The Sentosa platform is CE-IVD certified, with select tests holding FDA EUA, Australian TGA, and CLIA high-complexity authorizations, and the products comply with CFR 21 Part 11 for electronic records and signatures. Go-to-market combines regional direct sales (offices in Singapore for APAC/MEA, Hamburg for EMEA, and Fairfield NJ for the Americas) with a global distributor network, including a new exclusive EMEA distribution agreement with ABL Diagnostics (Euronext: ABLD) effective January 2026.

Vela was founded in 2011, operates with 101-250 employees, and is a subsidiary of Vela Diagnostics Holding Pte Ltd, which owns the registered trademarks for Sentosa, OncoKey, PathoKey, and ViroKey across the US, EU, PRC, and UK. The leadership team is led by Sam Dajani (Chairman and CEO), with Dr. Charlie Lee heading research and development and Scott Cassidy overseeing business development. The company acquired Lifecode's Data Interpretation Assets in May 2016 and received a modest Biomedical Advanced Research and Development Authority (BARDA) award of $225,000 in April 2020. There is no public listing and no disclosed venture or growth equity funding in the source material.

Vela Diagnostics Pte. Ltd. firmographics

Firmographics
Name
Vela Diagnostics Pte. Ltd.
Legal name
Vela Diagnostics Pte. Ltd.
Website
https://veladx.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Vela Diagnostics is a Singapore-based molecular diagnostics company providing integrated PCR and NGS sample-to-result solutions on the Sentosa platform. It serves hospital and oncology laboratories, research institutions, and pharmaceutical partners across the Americas, EMEA, and Asia Pacific.
Ownership category
akta.pro rank

Vela Diagnostics Pte. Ltd. industry classification

Industry
Product category
Molecular Diagnostics Instruments and Assays
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Molecular diagnostics platforms
  • Automated PCR workflows
  • Next-generation sequencing
  • Infectious disease testing
  • Clinical laboratory automation

Where Vela Diagnostics Pte. Ltd. is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices3 records

Markets served

Vela Diagnostics Pte. Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Instrument Sales: Sale of automated molecular diagnostics instruments including Sentosa SX101, SQ301, ST401, SA201, RGQ, and GB Analyzer. Instruments sold with perpetual licenses.
  2. Consumables and Reagents: Recurring sales of PCR and NGS assay kits, extraction kits, library preparation kits, sequencing kits, template kits, and chip kits. Consumables sold in packs of 4-96 tests.
  3. Software Licenses: Sale of software solutions including Sentosa SQ Reporter and SA Reporter with server and perpetual license options. Includes both IVD and RUO versions.
  4. Pharma Partnering: Collaborative partnerships with pharmaceutical companies for companion diagnostics development and validation.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goInstrument systems sold with perpetual licenses
Unit PricingPay-as-you-goPCR and NGS assay kits sold in pack sizes

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Vela Diagnostics Pte. Ltd. product offering

Product offering

Core offering

Vela Diagnostics designs, manufactures, and sells an integrated sample-to-result molecular diagnostics platform (Sentosa) that combines automated nucleic acid extraction, PCR setup, NGS template preparation, sequencing, and data analysis/reporting instruments, software, and validated assay kits for infectious disease, oncology, and antimicrobial resistance testing in clinical and reference laboratories.

Product overview

Vela Diagnostics is a global provider of integrated molecular diagnostics solutions offering standardized, automated PCR and NGS workflow products. The Sentosa platform provides an integrated sample-to-result system combining nucleic acid extraction (Sentosa SX101), PCR setup, template preparation (Sentosa ST401), sequencing (Sentosa SQ301), and automated data analysis/reporting (Sentosa SQ Reporter, Sentosa SA Reporter). The company offers broad PCR assay portfolios under the ViroKey and PathoKey brands covering infectious diseases (respiratory viruses including SARS-CoV-2, Monkeypox, influenza; virology including HIV, HCV, HBV, CMV; antimicrobial resistance), transplant monitoring (BKV, CMV, EBV, HSV, VZV, HHV6), and oncology (NGS-based cancer panels including OncoKey panels for NSCLC, leukemia, and hereditary cancer). The product ecosystem supports both fully automated high-throughput workflows (with <30 minutes hands-on time) and flexible manual options. The Sentosa platform is CE-IVD certified and FDA-cleared, with regulatory approvals across multiple global markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Sentosa: Automated platform for NGS and PCR testing workflows including instruments SX101, SQ301, ST401, and SA201
  • OncoKey
  • PathoKey
  • ViroKey

Products and services

  • Sentosa SX101

Quantifiable outcome

  • Up to 48 samples processed within 2 hours using SX101 automated extraction
  • +4 more outcomes

Companies that use Vela Diagnostics Pte. Ltd.

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Vela Diagnostics Pte. Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability9 records

Feature7 records

Vela Diagnostics Pte. Ltd. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ABL DiagnosticscoreChannel Partner/ Reseller/ Distributor · 28 July 2025Strategic channel partnership where ABL Diagnostics becomes the exclusive distributor of Vela's CE-IVD automated PCR and NGS platforms across Europe, Middle East, and Africa (EMEA), starting January 2026 following a non-exclusive transition phase in July 2025. The partnership combines Vela's automation and validated assay portfolio with ABL's specialized PCR/NGS kits, DeepChek NGS software, UltraGene real-time PCR kits, and Nadis electronic medical record system deployed in over 200 hospitals in France. ABL brings over two decades of molecular diagnostics experience and distribution in over 40 countries.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Vela Diagnostics Pte. Ltd. competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Vela Diagnostics Pte. Ltd. social profiles

Digital presence

Vela Diagnostics Pte. Ltd. compliance and trust

Trust signal

Compliance6 records

Vela Diagnostics Pte. Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vela Diagnostics Pte. Ltd. leadership team

Management profile

Number of profiles

Profiles8 records

Vela Diagnostics Pte. Ltd. funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vela Diagnostics Pte. Ltd. M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vela Diagnostics Pte. Ltd.

What does Vela Diagnostics Pte. Ltd. do?

Vela Diagnostics designs, manufactures, and sells an integrated sample-to-result molecular diagnostics platform (Sentosa) that combines automated nucleic acid extraction, PCR setup, NGS template preparation, sequencing, and data analysis/reporting instruments, software, and validated assay kits for infectious disease, oncology, and antimicrobial resistance testing in clinical and reference laboratories.

Is Vela Diagnostics Pte. Ltd. a public or private company?

Vela Diagnostics Pte. Ltd. is a private company. It is classified as corporate owned and is currently operating.

When was Vela Diagnostics Pte. Ltd. founded?

Vela Diagnostics Pte. Ltd. was founded in 2011. It employs 51 to 100 people.

Where is Vela Diagnostics Pte. Ltd. based?

Vela Diagnostics Pte. Ltd. is headquartered in Singapore, Singapore, in the Asia region.

How does Vela Diagnostics Pte. Ltd. make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables and Reagents, software Licenses and pharma Partnering.

Does Vela Diagnostics Pte. Ltd. have an API?

No public API is recorded for Vela Diagnostics Pte. Ltd..

What industry is Vela Diagnostics Pte. Ltd. in?

Vela Diagnostics Pte. Ltd.'s product category is Molecular Diagnostics Instruments and Assays. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingABL Diagnostics signs LOI to buy Vela Diagnostics units in Singapore, USABL Texcell Diagnostics signed a non-binding letter of intent to acquire Vela Diagnostics' operations in Singapore and the US from VDH Holding. The deal would extend coverage beyond EMEA into Asia-Pacific and the US, building on an existing EMEA distribution partnership. Completion is subject to due diligence and definitive documentation, with no change in control expected.EIN PresswireABL Diagnostics Drives EMEA Expansion with VELA Diagnostics PartnershipABL Diagnostics announced an exclusive partnership with VELA Diagnostics for EMEA, effective January 2026, to accelerate CE-IVD HIV testing. The company cites a 320K€ revenue run-rate in late 2025, projecting a 1M€ annualized baseline. It plans to deliver VELA HIV kits and transition to CE-IVDR-compliant solutions with the Sentosa platform in 2027.EIN PresswireABL Diagnostics and VELA Dx Expand Strategic Partnership with Key Commercial and Technical Milestones in EMEAABL Diagnostics and VELA Diagnostics announced major developments in their EMEA partnership, with ABL Diagnostics assuming reagent supply logistics from VELA Singapore by end of November 2025 and integrating several members of the VELA Europe team. The companies validated DeepChek® HIV assays on VELA's Sentosa® SX101 platform and confirmed DeepChek® Software integration, positioning both firms to capture share of a global sequencing-based genotyping market projected to exceed USD 3 billion by 2028.PR NewswireVela Diagnostics collabore avec SRL Inc. pour la distribution de produits au JaponVela Diagnostics signed a research collaboration agreement (ACR) with SRL Inc. in June 2023 to distribute its molecular diagnostic solutions in Japan, starting with feasibility studies for the HIV-1 SQ Sentosa® genotyping test kit. SRL Inc., a subsidiary of H.U Group Holdings Inc., operates over 80 commercial facilities across Japan and will leverage its distribution network to introduce Vela Diagnostics' automated next-generation sequencing solutions to Japanese healthcare institutions. The partnership aims to expand Vela Diagnostics' global HIV testing network to include Japan as a key market.PR NewswireVela Diagnostics colabora com SRL Inc. para distribuição de produtos no JapãoVela Diagnostics announced a research collaboration agreement with SRL Inc. to distribute its molecular diagnostic solutions in Japan, with the agreement signed in June 2023. The partnership aims to introduce Vela's FDA DeNovo-designated Sentosa® SQ HIV-1 Genotyping Assay to Japanese healthcare institutions through SRL's distribution network of over 80 business bases across the country. The companies expect the collaboration to expand Vela's global HIV testing network to include Japan, complementing its existing presence in the Americas, Africa, Europe, Middle East, Southeast Asia, and Australia.PR NewswireVela Diagnostics arbeitet mit SRL Inc. für den Produktvertrieb in Japan zusammenVela Diagnostics signed a research cooperation agreement (RCA) with SRL Inc. in June 2023 to distribute its molecular diagnostic solutions, starting with the Sentosa® SQ HIV-1 Genotyping Assay Kit, in the Japanese market. SRL Inc., a subsidiary of H.U Group Holdings Inc. with over 80 locations across Japan, has already begun feasibility studies for the kit, which received FDA DeNovo status in 2019. The partnership aims to leverage SRL Inc.'s distribution network to expand Vela Diagnostics' presence in Japan's healthcare sector and join its global network of HIV testing providers.PR NewswireVela Diagnostics colabora con SRL Inc. para la distribución de productos en JapónVela Diagnostics announced a research collaboration agreement (RCA) with SRL Inc., a major Japanese clinical laboratory services company, to distribute its molecular diagnostic solutions in Japan, with the agreement signed in June 2023. The partnership will leverage SRL Inc.'s distribution network to introduce Vela Diagnostics' Sentosa SQ HIV-1 genotyping assay, which received FDA DeNovo designation in 2019, to Japanese healthcare institutions, with SRL Inc. already conducting feasibility studies for the product.PR NewswireVela Diagnostics Supports COVID-19 Surveillance Efforts in KenyaVela Diagnostics has been appointed by the National Public Health Laboratory of Kenya as a supplier for SARS-CoV-2 genotyping tests, with funding provided by The Global Fund. This partnership supports Kenya's national program to trace and curb the spread of COVID-19 through advanced genomic surveillance.PR NewswireMedia Pooling Strategy to Increase Testing Throughput Added to Vela Diagnostics' ViroKey SARS-CoV-2 RT-PCR Test v2.0Vela Diagnostics added a three-in-one media pooling strategy to its ViroKey SARS-CoV-2 RT-PCR Test v2.0, enabling pooling of up to three nasal swab specimens. The FDA EUA-authorized indication allows use in CLIA-certified labs for qualitative detection of SARS-CoV-2 RNA, increasing testing throughput and reducing costs in low-positivity populations.PR NewswireVela Diagnostics lanza paneles pancancerosos basados en NGSVela Diagnostics announced the launch of two new pan-cancer panels based on next-generation sequencing — the OncoKey® SL 60 Plus (60 genes) and OncoKey® SL 525 Plus (525 genes) — designed for detecting cancer biomarkers from formalin-fixed paraffin-embedded tissue samples, supporting up to 64 samples in a single run. The panels feature a highly automated sample-to-result workflow capable of producing results in five days with only 2.5 hours of hands-on time, and are integrated with Illumina sequencing platforms. The company plans to launch both panels in the United States and Asia Pacific in the fourth quarter of 2022.